METHOD DEVELOPMENT AND ITS VALIDATION FOR QUANTITATIVE DETERMINATION OF BOSENTAN IN TABLET DOSAGE FORM BY RP-HPLC by Shahul, Hameed M et al.
Shahul et al                                                                                            Journal of Drug Delivery & Therapeutics. 2017; 7(2):85-95                                    
ISSN: 2250-1177                                                                                 [85]                                                                     CODEN (USA) JDDTAO 
Available online on 15.03.2017 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open access to Pharmaceutical and Medical research 
© 2011-17, publisher and licensee JDDT, This is an Open Access article which permits unrestricted 
noncommercial use, provided the original work is properly cited 
 
Research Article 
METHOD DEVELOPMENT AND ITS VALIDATION FOR 
QUANTITATIVE DETERMINATION OF BOSENTAN IN TABLET 
DOSAGE FORM BY RP-HPLC 
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ABSTRACT 
Objectives of this research work were development and validation of HPLC methods of analysis for Bosentan in tablet dosage form 
from single components as per the current ICH & USP guidelines. HPLC methods also validated for the marketed Bosentan from 
single components. This developed procedure applied for regular analysis of these medicaments in pharmaceutical industry The 
major scope of research is development of simple, accurate, reproducible & fast cost effective methods for new cefalosporins. The 
methods are validated with recovery studies using bulk drug of 80%, 120% & 40%. Specific method is confirmed by checking 
interference of excipients & assay method. The interday & intraday assay is also performed for checking robustness of the system. 
The minimum detection limit is checked by using formula LOD = 3.3 sigma (Standnd deviation) / Slop, where σ indicate standard 
deviation & S denotes slop of the regression straight line. The quantification limit is determined by using LOQ = 10 σ d(St&. dev.)/ 
S that is minimum concentration of drug can be quantified. Linearity is found in the limit of Beer’s law, straight line was constructed 
within the given range of the conc. of the drugs. So can develop & validate a new, reproducible, correct, & easy, less time 
consuming, cheap & eco-friendly method for daily analysis of drug in our general life. 
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________________________________________________________________________________________________ 
INTRODUCTION 
Bosentan is used to treat pulmonary hypertension by 
blocking the action of endothelin molecules that would 
otherwise promote narrowing of the blood vessels and 
lead to high blood pressure. Metabolism of Bosentan 
occurs mainly in the liver by the action of cytochrome P 
(CYP) 450 3A4 and 2C9, which produces three 
metabolites: the hydroxylated (hydroxy) metabolite, the 
demethylated (phenol) metabolite and the hydroxylated 
and demethylated (hydroxy-phenol) metabolite 
1-4
. 
Bosentan is chemically, 4-tert-butyl-N-[6-(2-
hydroxyethoxy) -5- (2-methoxyphenoxy) -2- (pyrimidin-
2-yl) pyrimidin-4-yl] benzene-1 sulfonamide 
5
. Various 
liquid chromatography techniques have been developed 
for the determination of bosentan in biological fluids 
6- 7
 
and tablet dosage forms 
8
. Karnaker RT, et al. (2010) 
reported RPHPLC procedure for the development & 
validation of Bosentan present in tab. formulations. The 
mobile phase was selected on the hit & trial basis. The 
run time for mobile phase is 1 ml/minutes & gradient 
technique was used for continue elution of mobile phase 
according to volume time ratio
8
.  
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The method was developed for bulk drug & then applied 
for pharmaceutical formulations. The method is 
validated for recovery studies (40, 80, 120%), linearity, 
(preparation of standard curve), detection of limit, limit 
of quantification, stability studies on temperature basis, 
specificity of instruments. The method was applied for 
routine analysis of drugs
10
. 
In the present study a simple, rapid, precise and accurate 
stability indicating liquid chromatographic method was 
developed for the determination of BST in in tablet 
dosage forms and validated as per ICH guidelines.
 
 
MATERIAL AND METHODS: 
1. Analytical Method Development
10,11 
1.1 Equipments  
The following instruments & equipments were used during the development studies: 
Table 1: List of Equipments 
HPLC instrument Waters 2695 separations module with 2487/2489 dual wavelength absorbance 
detector with Empower chromatographic software. 
pH meter Thermo-Orion star series 
Analytical balance Mettler Toledo 
Ultrasonic bath POWER SONIC420 “Aarkey” 
Water purification System Milli Q Gradient A 10 ,Elix A 10 “Millipore” 
 
1.2 Reagents & Chemicals 
The following reagents & chemicals were used during the validation studies: 
Table 2: List of reagents 
Sr. No. Name of the material Grade Make 
1 Potassium Dihydrogen ortho Phosphate ExcelaR Fisher Scientific 
2 Methanol HPLC S.D. Fine 
3 Acetonitrile HPLC Rankem 
4 Water HPLC Inhouse 
 
1.3 Working Standard 
The following Working standard was used during the 
develop studies: 
Bosentan in Salt form: Potency (%)  98.8 
1.4 Parameter Wise Method Development Plan
 
A.  Molecular weight: 
Molecular weight of Bosentan is 321.82gm & in salt 
form molecular weight is 419.7 gm.  
B.  Column selection: Non-polar columns  
C.  Detector selection: Bosentan is a UV active 
compound. Therefore, UV detector has been chosen for 
detection. 
D.   Selection of wavelength: max of Bosentan is 
220nm.  
E.  Mobile phase selection: In mobile phase preparation 
following solvent & buffer has been taken: 
a) Acetonitrile is used as it is having the UV-cut off 
190nm & is commonly used solvent. 
b) Phosphate buffer was selected as buffer: 1.36 gm 
potassium di-hydrogen   phosphate in 1 L Milli Q Water     
(pH Value-4.4)                                                                                                                               
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1.5 Method Development Trials 
Table 3: Trial no. 1 Chromatographic conditions  
Column Inertsil ODS-3V 
(150*4.6) mm,5µm  
Flow rate 1.0ml/min 
Detector wavelength 220nm 
Injection volume 10µL 
Sample temperature 25°C 
Column temperature 25°C 
Detector UV 
Diluent Buffer:ACN (75:25) 
Mobile phase B Acetonitrile 
Mobile phase A Buffer 
Run time 20 mins. 
 
Table 4: Trial no. 2 Chromatographic conditions  
Column Kromasil C 18 (150*4.6)  
mm, 5µm  
Sample temperature 25°C 
Injection volume 10µL 
Flow rate 1.0ml/min 
Detector wavelength 220nm 
Column temperature 25°C 
Detector UV 
Composition Buffer: ACN (75:25) 
Mobile phase B Acetonitrile 
Mobile phase A Buffer 
Run time 20 mins 
 
Table 5: Trial no. 3 Chromatographic conditions  
Column Zorbax C 8 (150*4.6) 
mm,5µm  
Sample temperature 25°C 
Injection volume 10µL 
Flow rate 1.0ml/min 
Detector wavelength 220nm 
Column temperature 25°C 
Detector UV 
Diluent BUFFER:ACN (75:25) 
Mobile phase B Acetonitrile 
Mobile phase A BUFFER 
Run time 20 mins. 
 
Table 6: Trial no. 4 Chromatographic conditions  
Column Ultron ES OVM (150*4.6) 
mm,5µm  
Sample temperature 25°C 
Injection volume 10µL 
Flow rate 1.0ml/min 
Detector wavelength 220nm 
Column temperature 25°C 
Detector UV 
Diluent BUFFER:ACN (60:40) 
Mobile phase B Acetonitrile 
Mobile phase A BUFFER 
Run time 20 mins. 
 
Table 7: Trial no. 5 Chromatographic conditions  
Column Ultron ES OVM-(150-
4.6) mm,5µm  
Sample temperature 25˚C 
Injection volume 10µL 
Flow rate 1.0ml/min 
Detector wavelength 220nm 
Column temperature 25°C 
Detector UV 
Coposition Buffer: ACN (90:10) 
Mobile phase B Acetonitrile 
Mobile phase A Buffer 
Run time 20 mins. 
 
Table 8: Trial no. 6 Chromatographic conditions     
 Column Ultron ES OVM (150*4.6) 
mm,5µm  
Sample temperature 25°C 
Injection volume 10µL 
Flow rate 1.0ml/min 
Detector wavelength 220nm 
Column temperature 25°C 
Detector UV 
Diluent BUFFER: ACN (80:20) 
Mobile phase B Acetonitrile 
Mobile phase A BUFFER 
Run time 20 mins 
 
Table 9: Trial no. 7 Chromatographic conditions  
Column Ultron ES OVM (150*4.6) 
mm, 5µm  
Sample temperature 25°C 
Injection volume 10µL 
Flow rate 1.2ml/min 
Detector wavelength 220nm 
Column temperature 25°C 
Detector UV 
Diluent BUFFER:ACN (80:20) 
Mobile phase B Acetonitrile 
Mobile phase A BUFFER 
Run time 20 mins. 
 
Table 10: Trial no. 8 Chromatographic conditions  
Column Ultron ES OVM (150*4.6) 
mm,5µm  
Sample temperature 25°C 
Injection volume 10µL 
Flow rate 1.2ml/min 
Detector wavelength 220nm 
Column temperature 25°C 
Detector UV 
Diluent BUFFER:ACN (80:20) 
Mobile phase B Acetonitrile 
Mobile phase A BUFFER 
Run time 20 mins. 
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2. Analytical Method Validation 
 
2.1 Objective: To demonstrate that Assay method of 
Bosentan by Reverse Phase-high performance liquid 
chromatography (RP-HPLC) is suitable for intended 
purpose. 
2.2 Scope: This validation study is applicable for 
Assay method of Bosentan, which will be used to 
ensure the identity, quality & purity of active 
pharmaceutical ingredient. 
2.3 Methodology 
2.3.1 Preparation of mobile phase-A 
Dissolved 1.36 gm of potassium dihydrogen phosphate 
to 1000 mL of HPLC grade water. Mixed well using a 
magnetic stirrer bar until completely mixed. The 
solution was filtered through a 0.45 m nylon 
membrane filter & degassed. 
2.3.2 Preparation of mobile phase-B: Acetonitrile 
(HPLC Grade) 
2.3.3 Preparation of standard solution 
Weighed accurately about 48 mg of Bosentan 
working/reference standard into 50 mL volumetric 
flask. Dissolve in 30 mL of Methanol & dilute to 
volume with methanol. Diluted 5 ml of this solution to 
50 ml Methanol 
2.3.4 Preparation of sample solution 
5 Intact tablet of Bosentan taken into 500 ml 
volumetric flask than added 10 ml of water & sonicate 
till disintegrated. Added about 400 ml of methanol & 
sonicated for 45 minutes than made up volume with 
methanol. Added 5 ml of this solution in to 50 ml 
volumetric flask & make up volume with methanol. 
3. System Precision
12
 
3.1 Chromatographic conditions  
Table 11: Chromatographic conditions 
Column Ultron ES OVM (150*4.6) mm,5µm  
Sample temperature 25°C 
Injection volume 10µL 
Flow rate 1.2ml/min 
Detector wavelength 220nm 
Column temperature 25°C 
Detector UV 
Diluent BUFFER:ACN (80:20) 
Mobile phase B Acetonitrile 
Mobile phase A BUFFER 
Run time 20 mins. 
 
3.2 HPLC analysis 
Purge injector, seal wash, needle wash, wet prime & 
equilibrate the HPLC system until a  steady baseline 
obtained (at least for 30 minutes) After the system has 
equilibrated & delta psi of system is less than 50, inject 
blank (Single injection), standard solution (5 replicate 
injection) & sample solution (in duplicate) into the 
chromatographic system.  
3.3 Acceptance criteria for system suitability 
1. The percentage relative standard deviation (%RSD) 
of drug peak areas for six replicate  
Injections of working standard solution should not be 
more than 2%. 
2. The tailing factor of standard peak should not be 
more than2.0 
3. The plate count of standard peak should be more 
than 2000. 
4. Method Precision: 
Methodology: 5 intact tablet of Bosentan taken into 
500 ml volumetric flask than added 10 ml of water & 
sonicate till disintegrated. Added about 400 ml of 
methanol & sonicated for 45 minutes than made up 
volume with methanol. Added 5 ml of this solution in 
to 50 ml volumetric flask & make up volume with 
methanol. 
The sample was prepared six times as per above 
methodology & injected in duplicate  into the HPLC 
system. 
5. Linearity  
Prepared system suitability solution & diluted standard 
solution as per STP. Injected blank, system suitability 
solution & diluted standard solution as per injection 
sequence. Checked the acceptance criteria for system 
suitability. 
5.1 Preparation of Linearity Stock Solution 
Weighed 99.52 gm of working standard in 100 ml 
volumetric flask. Added 30 ml of methanol & 
sonicated to dissolve. Made up volume with methanol. 
Prepared Linearity solution of 20%, 80%, 120%, 
160%, 240% by dilution of Linearity Stock solution as 
below 
 
Conc. (µg/mL) =  
Wt. taken (mg) x Volume of Stock Solution taken (mL) x Potency of St&ard (on as is basis) x   (Molecular Weight of Drug ‘X’) x1000 
----------------------------------------------------------------------------------------------------------------------------- ------------------- 
100 mL x Dilution (mL)     x    Molecular Weight of Bosentan salt form   x     100 
 
Acceptance criteria: Acceptance criteria for system suitability should pass. Correlation coefficient should not be less 
than 0.990. Linearity has passed as accepted criteria. 
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6. Accuracy 
Prepared system suitability solution & diluted standard 
solution as per STP. Injected blank, system suitability 
solution & diluted standard solution as per injection 
sequence. Checked the acceptance criteria for system 
suitability. 
6.1 Methodology 
Accuracy weighed placebo equivalent as given below 
mg of Bosentan tablets & about 148 mg of Bosentan in 
salt form in 500ml of volumetric flask & dissolved 
with methanol & made up volume with methanol. 
Further diluted 5 ml of above solution in to 50 ml 
diluents. Filtered with 0.45 µ filter & injected in to 
HPLC 
For 30% Accuracy- About 148 mg 
For 100% Accuracy- About 493 mg 
For 200% Accuracy- About 985 mg 
RESULTS AND DISCUSSION 
In order to get the increased efficiency of the 
chromatographic system, the conditions of experiment 
such as column, column temp, pH and composition of 
mobile phase, and detection wavelength were 
optimized by changing one parameter at a time and 
keeping the other parameters constant. In RP HPLC 
method, the primary requirement for developing a 
method for analysis is that the using different solvents 
and buffers and columns to get better retention time 
and theoretical plates, and better cost effective and 
time saving method than the previously developed 
methods. 
Method Development Trials 
Trial no.-1 
Trials Observations: 
 Run time is longer 
 Peak is not eluted. 
 Base line is not good.  
Corrections to next trial: Column need to be changed 
Trial no.-2 
Trials Observations: 
 Run time is longer 
 Peak is not eluted. 
 Base line is not good.  
Corrections to next trial: Column need to be changed 
Trial no.-3 
Trials Observations: 
 Run time is longer 
 Peak is not eluted. 
 Base line is not good.  
Corrections to next trial: Mobile Phase composition 
needs to be changed and Column need to be changed 
 
 
Trial No.4 
Trials Observations: 
 Run time is longer 
 Peak is not eluted. 
 Base line is good. 
 Peak might be eluting  earlier in dead volume due 
to increase ratio of Acetonitrile 
Corrections to next trial: Mobile Phase Composition 
needs to be changed 
Trial no.-5 
Trials Observations: 
 Base line is good but the retention of the Drug in the 
column was too much. 
 No Sharpness of the peaks. 
 Run time is too longer. 
 Peak is eluted too late 
 Tailing is high 
 .Plate count is low 
Corrections to next trial: Mobile phase composition 
needs to be changed. 
Trial No.6 
Trials Observations: 
 Run time is longer 
 Peak shape is good 
 Base line is good. 
 Peak is eluted late. 
Corrections to next trial: Flow rate need to be 
changed and Run time need to be changed 
Trial No.7 
Trials Observations: 
 Base line is good 
 Sharpness of the peaks is fine 
 Run time is optimum. 
 Retention time is good (earlier) 
 Tailing is low 
 Plate count is high 
Final Optimized Method 
Related chromatogram: for Standard Solution 
 
Related chromatogram: for Sample Solution 
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Analytical Method Validation 
 
Mobile phase-A is prepared by Dissolving 1.36 gm 
of potassium di hydrogen phosphate to 1000 mL of 
HPLC grade water. Mixed well using a magnetic 
stirrer bar until completely mixed. The solution was 
filtered through a 0.45 m nylon membrane filter & 
degassed. Mobile phase-B is prepared using 
Acetonitrile (HPLC Grade) 
Standard solution is prepared by Weighing 
accurately about 48 mg of Bosentan working/reference 
standard into 50 mL volumetric flask. Dissolve in 30 
mL of Methanol & dilute to volume with methanol. 
Diluted 5 ml of this solution to 50 ml Methanol 
System Precision 
Table 12: Chromatographic conditions 
Column Ultron ES OVM (150*4.6) mm,5µm  
Sample temperature 25°C 
Injection volume 10µL 
Flow rate 1.2ml/min 
Detector wavelength 220nm 
Column temperature 25°C 
Detector UV 
Diluent BUFFER:ACN (80:20) 
Mobile phase B Acetonitrile 
Mobile phase A BUFFER 
Run time 20 mins. 
 
 
Chromatograms of Standard: 
Injection-1 
 
Injection-2 
 
  Injection-3 
  
 Injection-4 
 
Injection-5 
 
Injection-6 
. 
               
Table 13: 
Standard Area Counts 
Injection Area 
1 1926300 
2 1937992 
3 1938435 
4 1934998 
5 1940483 
6 1938834 
Mean 1936174 
S.D. 5156.3 
% RSD 0.27 
 
Using the chromatography data acquisition system, 
integrate the peaks of standard solution.  
System suitability passes as per acceptance criteria. 
Method Precision: 
5 Intact tablet of Bosentan taken into 500 ml volumetric 
flask than added 10 ml of water & sonicate till 
disintegrated. Added about 400 ml of methanol & 
sonicated for 45 minutes than made up volume with 
methanol. Added 5 ml of this solution in to 50 ml 
volumetric flask & make up volume with methanol. The 
sample was prepared six times as per above 
methodology & injected in duplicate  into the HPLC 
system. 
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Chromatograms of Method Precision 
MP-1(Injection-1) 
 
MP-1(Injection-2) 
 
MP-2(Injection-1) 
 
MP-2(Injection-2) 
 
MP-3(Injection-1) 
 
MP-3(Injection-2) 
 
  MP-4(Injection-1) 
 
 MP-4(Injection-2) 
 
MP-5(Injection-1) 
 
MP-5(Injection-2) 
 
MP-6(Injection-1) 
 
  MP-6(Injection-2) 
 
 
Table 14: Calculation of Method Precision 
standard Area Counts 
Injection Area 
1 1926300 
2 1937992 
3 1938435 
4 1934998 
5 1940483 
Mean 1935642 
S.D. 5577.8 
% RSD 0.29 
 
Conclusion: Method Precision has passed as per acceptance criteria.  
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Linearity  
Prepared system suitability solution & diluted standard solution as per STP. Injected blank, system suitability solution 
& diluted standard solution as per injection sequence. Checked the acceptance criteria for system suitability. 
Chromatogram of Linearity 
Linearity at 20 %( Injection-1) 
 
 Linearity at 20 % (Injection-2) 
 
Linearity at 80 % (Injection-1) 
 
Linearity at 80% (Injection-2) 
 
Linearity at 120% (Injection-1) 
 
Linearity at 120 % (Injection-2) 
 
  Linearity at 160 % (Injection-1) 
 
 Linearity at 160 % (Injection-2) 
 
   Linearity at 240 % (Injection-1) 
 
 Linearity at 240 % (Injection-2) 
 
     
Preparation of Linearity Stock Solution 
Weighed 99.52 gm of working standard in 100 ml volumetric flask. Added 30 ml of methanol & sonicated to dissolve. 
Made up volume with methanol. Prepared Linearity solution of 20%, 80%, 120%, 160%, 240% by dilution of Linearity 
Stock solution as below 
Table 15: Preparation of Linearity Stock Solution 
Sample ID 
Linearity Stock 
Solution(mL) 
Dilution (mL) Linearity range (%) Conc. (µg/mL) 
Linearity - 1 2 100 20.1 15.08 
Linearity - 2 4 50 80.4 60.32 
Linearity - 3 6 50 120.6 90.47 
Linearity - 4 8 50 160.8 120.63 
Linearity - 5 6 25 241.3 180.95 
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Table 16: Calculation of Linearity  
Standard Area Counts 
Injection Area 
1 1926300 
2 1937992 
3 1938435 
4 1934998 
5 1940483 
Mean 1935642 
S.D. 5577.8 
% RSD 0.29  
Figure 1: Linearity plot of Bosentan 
Table 17: Calculation of Linearity  
Molecular Wt  of Bosentan: 321.82,  
Molecular Wt  of Bosentan salt form: 419.90, 
Preparation of Linearity Stock solution: 99.52 gm to    100ml  
Linearity range (%) Area Counts Average area 
counts 
Injection - 1 Injection - 2 
20.1 416230 415094 415662 
80.4 1610958 1598300 1604629 
120.6 2391854 2389445 2390650 
160.8 3237273 3244063 3240668 
241.3 4790309 4777574 4783942 
  Slope 26421.35 
  Intercept         16977.76 
Correlation Coefficient 0.9999 
Acceptance criteria: Acceptance criteria for system suitability should pass. Correlation coefficient should not be less 
than 0.990. Linearity has passed as accepted criteria. 
 
Accuracy 
Prepared system suitability solution & diluted standard solution as per STP. Injected blank, system suitability solution 
& diluted standard solution as per injection sequence. Checked the acceptance criteria for system suitability. 
Accuracy at 30 %( Preparation-1, Injection-1) 
 
 Accuracy at 30 %( Preparation-1, Injection-2) 
 
Accuracy at 30 %( Preparation-2, Injection-1) 
 
Accuracy at 30 %( Preparation-2, Injection-2) 
 
Accuracy at 30 %( Preparation-3, Injection-1) 
 
Accuracy at 30 %( Preparation-3, Injection-2) 
 
 Accuracy at 100 %( Preparation-1, Injection-1) 
 
  Accuracy at 100 %( Preparation-1, Injection-2) 
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Accuracy at 100 %( Preparation-2, Injection-1) 
 
Accuracy at 100 %( Preparation-2, Injection-2) 
 
 Accuracy at 100 %( Preparation-3, Injection-1) 
 
Accuracy at 100 %( Preparation-3, Injection-2) 
 
  Accuracy at 200 %( Preparation-1, Injection-1) 
 
Accuracy at 200 %( Preparation-1, Injection-2) 
 
 
 Accuracy at 200 %( Preparation-2, Injection-1) 
 
Accuracy at 200 %( Preparation-2, Injection-2) 
 
Accuracy at 200 %( Preparation-3, Injection-1) 
 
Accuracy at 200 %( Preparation-3, Injection-2) 
 
Table 18: Calculation of Accuracy 
Standard Area Counts 
Injection Area counts 
1 1926300 
2 1937992 
3 1938435 
4 1934998 
5 1940483 
Mean 1935642 
S.D. 5577.8 
% RSD 0.29 
 
Table 19:  
Sample ID Accuracy  
Level 
Weight taken 
(mg) 
Actual 
Amount 
Added (mg) 
Conc. 
(µg/mL) 
Area Counts 
Inj.1 Inj.2 Mean Area 
Accuracy-30%-1 29.9 147.91 112.00 22.40 586163 586154 586159 
Accuracy-30%-2 148.01 112.08 22.42 586244 586289 586267 
Accuracy-30%-3 148.23 112.24 22.45 586348 586326 586337 
Accuracy-100%-1 99.5 492.84 373.19 74.64 1944499 1944498 1944499 
Accuracy-100%-2 492.92 373.25 74.65 1954631 1954335 1954483 
Accuracy-100%-3 493.10 373.39 74.68 1964521 1965421 1964971 
Accuracy-200%-1 198.9 984.98 745.85 149.17 3856895 3856785 3856840 
Accuracy-200%-2 985.19 746.01 149.20 3885687 3886789 3886238 
Accuracy-200%-3 985.46 746.21 149.24 3918568 3915678 3917123 
 
Table 20: Accuracy recovery 
Sample ID Accuracy Level 
Amount          
Recovered (mg) 
% 
Recovery 
  
  
Accuracy-30%-1 
29.9 
112.13 100.12 Mean 100.04 
Accuracy-30%-2 112.15 100.06 SD 0.097 
Accuracy-30%-3 112.16 99.93 % RSD 0.10 
Accuracy-100%-1 
99.5 
371.98 99.68 Mean 100.17 
Accuracy-100%-2 373.89 100.17 SD 0.495 
Accuracy-100%-3 375.89 100.67 % RSD 0.49 
Accuracy-200%-1 
198.9 
737.80 98.92 Mean 99.66 
Accuracy-200%-2 743.43 99.65 SD 0.750 
Accuracy-200%-3 749.33 100.42 % RSD 0.75 
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Table 21: Compiled Recovery Data 
Sample Name Accuracy 
Level 
% Recovery 
Accuracy-30%-1 29.9 100.12 
Accuracy-30%-2 100.06 
Accuracy-30%-3 99.93 
Accuracy-100%-1 99.5 99.68 
Accuracy-100%-2 100.17 
Accuracy-100%-3 100.67 
Accuracy-200%-1 198.9 98.92 
Accuracy-200%-2 99.65 
Accuracy-200%-3 100.42 
Overall Mean 99.96 
Overall SD 0.361 
Overall %RSD 0.36 
 
CONCLUSION 
An Analytical method for Assay of Bosentan Tablet was 
developed by Reverse phase High performance liquid 
chromatography by using different columns ,different 
mobile phase ratio & different chromatographic conditions 
& finally optimized using best chromatographic conditions.  
The method was validated by the following parameters, 
system precision, method precision, accuracy, & linearity. 
All these parameters have passed as per acceptance criteria.   
Finally in a concise & fruitful way, the developed method 
found to have several advantages over Traditional method: 
 The method is cheap – Only 5 Tablets require at the 
place of 20 Tablets. 
 The method is more accurate – In Direct intact method 
there is very less chances of contamination as compare 
to crush method. 
 The method is easy to run – Developed method is easier 
as compare to crush method. 
 The method consume Less time – Direct intact method 
has ability to save time of crushing, & shorter run time 
in chromatography. 
There are five drugs that are analyzed in this research work. 
All drug have the same application as antihypertensive 
agents to relive the blood pressure. The drug are newer in 
this category. The drug bosentan is angiotensin II 
antagonist & latest in this category. The method for 
analysis is developed with high performance liquid 
chromatography. The method is simple, easy, accurate, 
sensitive, cost effective & rapid. The method is validated 
according to international conference of hormonization for 
accuracy, precision, correctness, reproducibility, range, 
linearity, limit of detection, limit of quantification, 
robustness, ruggdness, & system suitability parameters. The 
method is then applied to marketed formulations. The 
method of analysis of bosentan can be applied for daily 
routine analysis of bulk drug bosentan & its marketed 
formulations. 
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